Physician profile
Kumar Sarvottam
NPI 1740630888
$4,436.55
in general payments reported to CMS, 2019-2025
11 companies · $3,989 in 2025
The $3,989 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.70 · 2022: $146 · 2023: $127 · 2024: $137 · 2025: $3,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,557 · Travel and Lodging: $1,306 · Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,557.48 |
| Travel and Lodging | $1,306.05 |
| Food and Beverage | $389.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,823.04 | 2025 | |
| Mylan Specialty L.P. | $137.21 | 2022-2023 | Yupelri |
| Steris Corporation | $114.08 | 2025 | |
| Medtronic, INC. | $61.92 | 2023 | Illumisite |
| Glaxosmithkline, LLC. | $58.35 | 2020-2024 | Nucala |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Amgen INC. | $49.29 | 2022-2023 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $41.94 | 2023-2025 | Fasenra, Airsupra |
| Ani Pharmaceuticals, INC. | $34.65 | 2025 | Purified Cortrophin Gel |
| Tactile Systems Technology INC | $34.05 | 2024 | Entre Plus, Flexitouch Plus |
| Mallinckrodt Hospital Products INC. | $24.54 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Sarvottam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.